Da zakažete pregled pozovite 063 687 460
Zakažete pregled 063 687 460
Najnoviji odgovori (95484)
-
Imam neobjasnjiv zadah iz usta kao iz mrtvacnice, unutrasnji organi su mi zdravi, zubi su takodje zdravi, redovno cistim kamenac itd, jedino sto ceo zivot imam veliki sloj belih naslaga na jeziku koji se jedva skida... da li mozda imate ideju koji su potencijalni uzroci, bakterije itd koji uticu na to ili postoji mogucnost da je to nasledno? i koje preglede bih trebala da uradim?
Odgovoreno: 21. 10. 2025.-
Zakazite pregled u Poliklinici Roncevic.
-
Dobar dan,imam jedno pitanje.Dijete 2 godine je imalo 11.9 operaciju trećeg krajnika i ugrađivali su mu cjevcice u uši zbog lošeg testa sluha.Od 11 mjeseca prošle godine je popio 11 puta antibiotik,Imao je problema sa uvecanim limfnim cvorovima, na obadvoje strane vrata i iza uha.Rekli su nam da je to sve od stalnih upala.Nakon operacije vec 4 puta je imao temperaturu i iz desnog uha mu je dva dana nakon operacije izlazila krv,sada vec nakon mjesec od operacije mu izlazi kao zeleni iscjedak koji ima jako neugodan miris.vodili smo ga opet doktoru međutim oni su rekli da je sa ušima sve uredu.Molim vas pomoć da li je to uredu.Limfni cvorovi su i dalje povećani nisu se povukli na desnoj strani mu je ovaj jedan limfni cvor 2.8cm.
Odgovoreno: 21. 10. 2025.-
Ovo se sliva gnojni sekret - bakterijska infekcija najverovatnije. Dete ima infekciju i treba da se leci. Javite se vasem doktoru.
Prijavite se
Dobro došli! Unesite svoje login podatke
ZAKAZIVANJE 063/687-460 -
-
Da li postoje opasni i bezopasni hpv virusi?
Odgovoreno: 24. 10. 2025.postoje neki koji mogu da izazovu onkogenezu. te otuda preoruka o vakcinaciji, prilažem tekst iz ugžbenika
Human Papillomavirus (HPV) Vaccine
Human papillomavirus (HPV) infection is the most common sexually transmitted infection. HPV can cause skin warts, genital warts, or certain cancers, depending on the type of HPV. Vaccines have high efficacy for the primary prevention of infection with HPV strains that can cause anogenital warts and cervical cancer (1). However, use of the HPV vaccine does not eliminate the need for continued Papanicolaou (Pap) test screening because some cervical cancers are caused by HPV types not included in the vaccine. Immunization usually leads to long-lasting immunity.
(See also Overview of Immunization.)
General reference
1. Markowitz LE, Unger ER. Human Papillomavirus Vaccination. N Engl J Med. 2023;388(19):1790-1798. doi:10.1056/NEJMcp2108502
Preparations of HPV Vaccine
Three vaccines protect against HPV:
A human papillomavirus nonavalent (9vHPV) vaccine that protects against HPV types 6 and 11 (which cause > 90% of visible genital warts), types 16 and 18 (which cause approximately 70% of cervical cancers and 90% of anal cancers), and types 31, 33, 45, 52, and 58 (which together cause 10 to 20% of cervical cancers [1])
A human papillomavirus quadrivalent vaccine (4vHPV) that protects against types 6, 11, 16, and 18
A human papillomavirus bivalent vaccine (2vHPV) that protects against types 16 and 18
Only the 9-valent vaccine is available in the United States.
Recombinant DNA technology is used to prepare HPV vaccines from the major capsid (L1) protein of HPV. The L1 proteins self-assemble into noninfectious, nononcogenic virus-like particles (VLPs).
Preparations reference
1. National Cancer Institute. Human Papillomavirus (HPV) Vaccines. Accessed March 24, 2025.
Indications for HPV Vaccine
The HPV vaccine is a routine childhood vaccination. The 9-valent vaccine has been expanded to include adults age 27 through 45 years for the prevention of certain HPV-related cancers and diseases.
The recommendations from the Advisory Committee on Immunization Practices (ACIP) are the following (1–3):
For patients up to age 26 years: HPV vaccine is recommended at age 11 or 12 years (can start at age 9 years; recommended to start at age 9 if there is a history of sexual abuse or assault) and for previously unvaccinated or not adequately vaccinated patients up through age 26 years.
For adults 27 to 45 years: Clinicians should engage in a shared decision-making discussion with patients to determine whether they should be vaccinated.
The American Academy of Pediatrics (AAP) recommends HPV vaccination between the ages of 9 and 12 years, at an age the pediatric health care professional deems optimal for acceptance and completion of the vaccination series, and for previously unvaccinated or not adequately vaccinated patients up through age 18 (4, 5).
Alternatively (for consideration outside the United States), the following may be used:
4vHPV or 2vHPV for females
4vHPV for males, including those who have sex with men
Indications references
1. Centers for Disease Control and Prevention (CDC). HPV Vaccination Recommendations. Accessed September 23, 2025.
2. CDC. Adult Immunization Schedule by Age. Accessed September 23, 2025.
3. CDC. Human papillomavirus vaccination: Special situations. Accessed September 23, 2025.
4.American Academy of Pediatrics (AAP). Recommended Child and Adolescent Immunization Schedule for Ages 18 Years or Younger. Accessed September 23, 2025.
5. AAP. Human papillomavirus vaccination: Special situations. Accessed September 23, 2025.
Contraindications and Precautions for HPV Vaccine
Contraindications for HPV vaccine include:
A severe allergic reaction (eg, anaphylaxis) after a previous dose or to a vaccine component
Hypersensitivity to yeast
Pregnancy
Although HPV vaccines are not recommended for pregnant patients, pregnancy testing is not needed before vaccination. If pregnancy is diagnosed after the vaccination series has been started, no intervention is needed, but the remaining doses of the series should be delayed until pregnancy is completed.
The main precaution with HPV vaccine is:
Moderate or severe acute illness with or without fever (vaccination is postponed until the illness resolves)
Dose and Administration of HPV Vaccine
The HPV vaccine dose is 0.5 mL IM, administered in a 3-dose or 2-dose series depending on age at initial HPV vaccination.
Initial dose at age 9 to 14 years: A 2-dose series is administered at 0 and 6 to 12 months. Minimum interval between doses is 5 months. If a dose is administered too soon (in < 5 months), 1 additional dose should be administered.
Initial dose at age ≥ 15 years: A 3-dose series is administered at 0, 1 to 2 months, and 6 months. Minimum intervals are 4 weeks between the first and second dose, 12 weeks between the second and third doses, and 5 months between the first and third doses. If the second or third dose is administered too soon it should be repeated.
Some adults aged 27 to 45 years: Based on a shared clinical decision-making discussion, adults in this age group may complete the 2-dose series (if initiated at age 9 to 14 years) or 3-dose series (if initiated at ≥ 15 years) (see CDC: Shared Clinical Decision-Making: HPV Vaccination for Adults Aged 27-45 Years).
People with immunocompromising conditions, including HIV infection: Immunocompromised patients are given the 3-dose series as above, regardless of age at initial vaccination.
Adverse Effects of HPV Vaccine
Common adverse reactions include the following:
Injection site reactions such as pain, swelling, erythema, pruritis, and bruising
Fever
Nausea
Dizziness
For more information about adverse effects of these vaccines, refer to the prescribing information.
More Information
The following English-language resources may be useful. Please note that The Manual is not responsible for the content of these resources.
Advisory Committee on Immunization Practices (ACIP): ACIP Recommendations: Human Papillomavirus (HPV) Vaccine
Centers for Disease Control and Prevention (CDC): HPV (Human Papillomavirus)
American Academy of Pediatrics (AAP): Recommended Child and Adolescent Immunization Schedule for Ages 18 Years or Younger
European Centre for Disease Prevention and Control (ECDC): Human Papillomavirus Infection: Recommended vaccinations